Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies

Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies

Glioblastoma (GBM), a highly invasive and vascular malignancy is shown to rapidly develop resistance and evolve to a more invasive phenotype following bevacizumab (Bev) therapy. Rho Guanine Nucleotide Exchange Factor proteins (RhoGEFs) are mediators of key components in Bev resistance pathways, GBM...

Full description

Bibliographic Details
Main Authors: Kate Connor, David W. Murray, Monika A. Jarzabek, Nhan L. Tran, Kieron White, Patrick Dicker, Kieron J. Sweeney, Philip J. O’Halloran, Brian MacCarthy, Liam P. Shiels, Francesca Lodi, Diether Lambrechts, Jann N. Sarkaria, Raymond M. Schiffelers, Marc Symons, Annette T. Byrne
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
glioblastoma
bevacizumab resistance
anti-invasive therapy
RhoGEF
Beta-Pix/COOL-1
ARHGEF7
Online Access:https://www.mdpi.com/2072-6694/12/12/3531

Internet

https://www.mdpi.com/2072-6694/12/12/3531

Similar Items